Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 6/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31497822 | 0.85 | VEGFA (0.45) | VEGFAEPAS1SLC6A3HTR1ASLC6A2 | |
| SCHEMBL31497804 | 0.79 | VEGFA (0.50) | VEGFAEPAS1 | |
| SCHEMBL31497868 | 0.79 | VEGFA (0.39) | VEGFAEPAS1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL31497811 | 0.79 | VEGFA (0.55) | VEGFAEPAS1 | |
| SCHEMBL31497978 | 0.77 | VEGFA (0.42) | VEGFAEPAS1 | |
| SCHEMBL31497915 | 0.76 | VEGFA (0.54) | VEGFAEPAS1CYP2C9 | |
| SCHEMBL31497867 | 0.72 | VEGFA (0.41) | VEGFAEPAS1SLC6A3CYP3A4CYP1A2 | |
| SCHEMBL21005013 | 0.68 | VEGFA (0.68) | VEGFAEPAS1 | |
| SCHEMBL21005226 | 0.67 | VEGFA (0.64) | VEGFAEPAS1 | |
| SCHEMBL31497820 | 0.67 | VEGFA (0.40) | VEGFAEPAS1CYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025031396-A1 | SUBSTITUTED BENZOCYCLOBUTENE COMPOUND AND USES THEREOF IN THE FIELD OF MEDICINE | 杭州安道药业有限公司 | 2025-02-13 | — | — | WO | disclosed |